EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer

Pashtoon Murtaza Kasi iD, Manuel Geroy Afable, Cameron Herting, Mariusz Lukanowski, Zhaohui Jin iD

The Oncologist · 11.12.2023 · 28 (12) · 1034-1048

DOI: 10.1093/oncolo/oyad262 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 29.09.2023. Verfasst von Pashtoon Murtaza Kasi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology/Hematology, Division of Internal Medicine, Weill Cornell Medicine, Meyer Cancer Center, Englander Institute of Precision Medic…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer is the third most common cancer worldwide, and incidence is rising in younger individuals. Anti-EGFR antibodies, including cetuximab and panitumumab, have been incorporated into standard-of-care practice for patients with advanced disease. Herein, we review the molecular characteristics of these agents and the trials that lead to their approvals. Further, we discuss clinical implications of data regarding biomarkers that dictate treatment selection, different dosing strategies, and side effect management. Finally, we look towards the future and describe contexts in which these agents are currently being investigated clinically with a focus on combinations with MAPK-targeted therapies and immunotherapy. Overall, this review provides historical context, current clinical usage, and future directions for anti-EGFR antibodies in advanced colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsColorectal NeoplasmsHumansAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedErbB ReceptorsCetuximab

Substanzen

Antibodies, MonoclonalAntineoplastic AgentsAntibodies, Monoclonal, HumanizedErbB ReceptorsCetuximab

Autor:innen und Institutionen

  • Department of Oncology/Hematology, Division of Internal Medicine, Weill Cornell Medicine, Meyer Cancer Center, Englander Institute of Precision Medicine, New York, NY, USA.
  • Medical Affairs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Department of Oncology, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Pashtoon Murtaza Kasi, Zhaohui Jin

Förderung

  • Eli Lilly and Company

Zitieren

APA

Kasi, P. M., Afable, M. G., Herting, C., Lukanowski, M., & Jin, Z. (2023). Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer. The Oncologist, 28(12), 1034-1048. https://doi.org/10.1093/oncolo/oyad262

Vancouver

Kasi PM, Afable MG, Herting C, Lukanowski M, Jin Z. Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer. The Oncologist. 2023;28(12):1034-1048. doi:10.1093/oncolo/oyad262

BibTeX
@article{Kasi2023,
  author = {Kasi, Pashtoon Murtaza and Afable, Manuel Geroy and Herting, Cameron and Lukanowski, Mariusz and Jin, Zhaohui},
  title = {Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {12},
  pages = {1034--1048},
  doi = {10.1093/oncolo/oyad262}
}
Kostenlos starten →